BioMarin Pharma (BMRN) Tops Q2 EPS by 61c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $115 at Evercore ISI
August 6, 2024 5:02 AM EDTEvercore ISI analyst Cory Kasimov raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $115.00 (from $113.00) while maintaining a Outperform rating.
The analyst comments "BMRN printed an encouraging 2Q beat-and-raise w/ solid progress for Voxzogo and long-awaited strategic direction not to mention... More
